@FiercePharma: Sources: Bayer offers animal health biz, cash for Merck's OTC unit. News | Follow @FiercePharma
@TracyStaton: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton
@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Advair slide, China woes drop-kick Glaxo profits in Q1. Article | Follow @CarlyHFierce
> Generic injectable drug specialist Hospira ($HSP) reported a 6.3% rise in Q1 sales of just over $1 billion compared to adjusted net sales in the same quarter a year ago. Release
> Novartis ($NVS) got FDA approval for Zykadia (ceritinib) for treating patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Release
> Endo Health Solutions ($ENDP) has agreed to buy Mexico's Somar, a privately owned specialty pharma company, for an undisclosed amount. Report
> Franklin, TN-based Rare Disease Therapeutics has gotten FDA approval for Purixan (mercaptopurine) 20 mg/mL oral suspension, a liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL). Release
> Japan's Otsuka Pharmaceutical has been granted EU approval for its delamanid tuberculosis drug, for treating pulmonary multidrug-resistant tuberculosis in adult patients. Story
> Italian pharmaceutical company Rottapharm Madaus, which is controlled by the Rovati family in Italy, has filed to be listed on the stock exchange in Milan. Report
@FierceMedDev: The latest FierceDiagnostics is out, with scoops on Quest Diagnostics, Roche, VC funding and more. Read | Follow @FierceMedDev
@VarunSaxena2: Zogenix retaining rights to DosePro delivery technology in transaction with Endo. Story via FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: ICYMI here's yesterday's issue of FierceBiotech Research (stories on MERS, Alzheimer's and HIV). Read | Follow @EmilyWFierce
@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. More via FierceDrugDelivery | Follow @MichaelGFierce
> FDA deems faulty HeartWare tech potentially deadly. News
> Medtronic reveals positive data from new TAVR study for extreme-risk patients. More
> Teleflex teams up with Intuitive on next-gen da Vinci tech. Article
Biotech News
@FierceBiotech: GSK ups odds on heart drug hopeful with a changeup in endpoints. Story | Follow @FierceBiotech
@JohnCFierce: So after years of watching U.K. R&D get carved up like a cooked goose, lawmakers now want to probe the Pfizer deal? More | Follow @JohnCFierce
@DamianFierce: This list, via @JacobEPVantage, is like looking at an old yearbook. Qnexa was cute. I don't even recognize Sovaldi. Report | Follow @DamianFierce
@EmilyMFierce: ICYMI here's yesterday's issue of FierceBiotech Research: Report | Follow @EmilyMFierce
> Biopsy snafu torpedoes PhII prostate cancer data for Nymox. More
> Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada. Story
> Regeneron R&D chief's compensation shrinks, but still tops the chart. Article
Drug Delivery News
> Zogenix retaining rights to DosePro delivery technology in transaction with Endo. News
> Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Report
> Civitas announces positive results from Phase II inhaled levodopa trial. Story
> Cynapsus makes progress on sublingually delivered Parkinson's therapy. More
> Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles. Article
> Imaging technique maps transdermal drug migration. Item
Diagnostics News
> Seattle firm attracts $47.25M for blood test that confirms benign lung nodules. News
> A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi. Story
> Two new osteoarthritis biomarkers eyed for predictive Dx. More
> Quest to unveil new epilepsy tests in the wake of disappointing Q1 numbers. Article
> Roche-Evotec biomarker collaboration scores its first big milestone. Story
Pharma Marketing News
> Merck recruits ex-Law & Order star for new diabetes campaign. News
> With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting? Report
> Sanofi bucks unit-sale trend with plan to unload $7B worth of older products. Item
> It's make-or-break time for GSK's new sales model as Anoro hits the U.S. market. Story
> GlaxoSmithKline dispatches sales and marketing team to clean up in China. More
> Simplify the DTC roll call of side effects? Yes, please, drugmakers tell FDA. Article
And Finally... The Andhra Pradesh High Court in India has put a temporary hold on Sun Pharmaceutical's $3.2 billion purchase of Ranbaxy Laboratories, while it considers a case brought by investors alleging insider trading ahead of the announcement. Story